ReviewHematology. American Society of Hematology. Education Program2025
Challenges and opportunities in the long-term management of immune-mediated TTP.
Review in Hematology. American Society of Hematology. Education Program, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The quiet brain injury in thrombotic thrombocytopenic purpura: Are we missing the warning signs?British journal of haematology · 2026Article
- Unmet health care needs in immune thrombotic thrombocytopenic purpura survivors.Research and practice in thrombosis and haemostasis · 2026Article
- Current standards and novel concepts in thrombotic thrombocytopenic purpura.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnostic and treatment advances have revolutionized the landscape of immune-mediated thrombotic thrombocytopenic purpura (iTTP). With the widespread availability of ADAMTS13 testing and novel therapies, outcomes based primarily on platelet counts are no longer sufficient. Clinical definitions have recently been updated to reflect this progress. Given the efficacy of preemptive rituximab in preventing clinical relapses, experts now recommend every 3-month monitoring of ADAMTS13 in remission. With improved survival, long-term sequelae-including obesity, cardiovascular disease, chronic kidney disease, neuropsychiatric impairment, obstetric complications, and reduced life expectancy-are increasingly being recognized. This review explores the evolving landscape of long-term management in immune-mediated thrombotic thrombocytopenic purpura, highlighting current challenges in surveillance, immune suppression in the second line (and beyond), and emerging opportunities for recognition of long-term sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.